Redox modifications of cysteine-containing proteins, cell cycle arrest and translation inhibition: Involvement in vitamin C-induced breast cancer cell death

Nadine El Banna, Elie Hatem, Amélie Heneman-Masurel, Thibaut Léger, Dorothée Baille, Laurence Vernis, Camille Garcia, Sylvain Martineau, Corinne Dupuy, Stéphan Vagner, et al.

To cite this version:

Nadine El Banna, Elie Hatem, Amélie Heneman-Masurel, Thibaut Léger, Dorothée Baille, et al.. Redox modifications of cysteine-containing proteins, cell cycle arrest and translation inhibition: Involvement in vitamin C-induced breast cancer cell death. Redox Biology, Elsevier, 2019, 26, pp.101290. 10.1016/j.redox.2019.101290. hal-02389344

HAL Id: hal-02389344
https://hal-cnrs.archives-ouvertes.fr/hal-02389344
Submitted on 2 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Research Paper

Redox modifications of cysteine-containing proteins, cell cycle arrest and translation inhibition: Involvement in vitamin C-induced breast cancer cell death

Nadine El Banna, Elie Hatema, Amélie Heneman-Masurel, Thibaut Léger, Dorothee Baille, Laurence Vernis, Camille Garcia, Sylvain Martineau, Corinne Dupuy, Stephane Vagner, Jean-Michel Camadro, Meng-Er Huang

Institut Curie, PSL Research University, CNRS UMR 3348, Université Paris-Sud, Université Paris-Saclay, Orsay, France
Institut Jacques Monod, CNRS UMR 7592, Mass Spectrometry Laboratory, Université Paris Diderot, Paris, France
Institut Gustave Roussy, CNRS UMR 8200, Université Paris-Sud, Villejuif, France

ARTICLE INFO

Keywords:
Vitamin C
Ascorbic acid
Dehydroascorbic acid
Breast cancer
Oxidative stress
Redoxome

ABSTRACT

Vitamin C (VitC) possesses pro-oxidant properties at high pharmacologic concentrations which favor repurposing VitC as an anti-cancer therapeutic agent. However, redox-based anticancer properties of VitC are yet partially understood. We examined the difference between the reduced and oxidized forms of VitC, ascorbic acid (AA) and dehydroascorbic acid (DHA), in terms of cytotoxicity and redox mechanisms toward breast cancer cells. Our data showed that AA displayed higher cytotoxicity towards triple-negative breast cancer (TNBC) cell lines in vitro than DHA. AA exhibited a similar cytotoxicity on non-TNBC cells, while only a minor detrimental effect on noncancerous cells. Using MDA-MB-231, a representative TNBC cell line, we observed that AA- and DHA-induced cytotoxicity were linked to cellular redox-state alterations. Hydrogen peroxide (H2O2) accumulation in the extracellular medium and in different intracellular compartments, and to a lesser degree, intracellular glutathione oxidation, played a key role in AA-induced cytotoxicity. In contrast, DHA affected glutathione oxidation and had less cytotoxicity. A “redoxome” approach revealed that AA treatment altered the redox state of key antioxidants and a number of cysteine-containing proteins including many nucleic acid binding proteins and proteins involved in RNA and DNA metabolisms and in energetic processes. We showed that cell cycle arrest and translation inhibition were associated with AA-induced cytotoxicity. Finally, bioinformatics analysis and biological experiments identified that peroxiredoxin 1 (PRDX1) expression levels correlated with AA differential cytotoxicity in breast cancer cells, suggesting a potential predictive value of PRDX1. This study provides insight into the redox-based mechanisms of VitC anticancer activity, indicating that pharmacologic doses of VitC and VitC-based rational drug combinations could be novel therapeutic opportunities for triple-negative breast cancer.

1. Introduction

Reactive oxygen species (ROS) homeostasis and intracellular reductive/oxidative (redox) dynamics play a key role in regulating cell viability or death. Mounting evidence has established that defects in redox signaling and oxidative stress are at the crux of various pathological processes. Notably, one of the significant features of cancer cells, when compared to their normal counterparts, is a persistent pro-oxidative state. In cancer cells, cellular events such as activation of oncogenes, aberrant metabolic stress and mitochondrial dysfunction can increase ROS levels, leading to intrinsic oxidative stress [1,2]. Therefore, the administration of a ROS-generating agent or antioxidant inhibitor could increase ROS levels to a threshold that is incompatible with viability, selectively and preferentially affecting cancer cells [1–3].

Vitamin C (VitC) is an essential nutrient used as a co-factor by numerous biosynthetic enzymes. It exists in the parental reduced form or ascorbic acid (AA, or AscH2) and the oxidized forms, encompassing the ascorbate radical (Asc•–) and the dehydroascorbic acid (DHA). At physiological pH (7.0), the dominant species for VitC is ascorbate.
monooanion (AscH−, 99.9%), with low concentrations of AscH2 (0.1%) and ascorbate dianion (Asc2−, 0.005%) [4]. The ability to donate one or two electrons makes ascorbate (AscH−) an excellent reducing agent and antioxidant. At millimolar levels (pharmacologic concentrations), AA becomes a ROS-generating molecule. In fact, a small portion of AA, via the ascorbate dianion (Asc2−), can undergo limited pH-dependent auto-oxidation that can lead to superoxide anion (O2•–) formation according to the following reaction: Asc2− + O2 → Asc•– + O2− [4,5]. Superoxide anions subsequently disproportionate to produce H2O2 (O2•– + O2− + 2H+ → H2O2 + O2). Importantly, in the presence of redox active metal ions, AA oxidation is further accelerated and amplified as ascorbate (AscH−) can exert an additional pro-oxidant effect. AscH− donates one electron to metals, that can reduce ferric (Fe3+) to ferrous (Fe2+) iron for example, while being oxidized to ascorbic radical (AscH + Fe3+ → Asc•− + Fe2+ + H+). Fe2+ can readily react with O2−, reducing it to superoxide anion (O2 + Fe2+ → O2•– + Fe3+), which in turn dismutates to H2O2 and O2 [4,5]. These mechanisms act to produce a high flux of H2O2 at pharmacologic concentrations of AA. In a classic Fenton reaction, Fe2+ reacts with H2O2 to generate Fe3+ and the highly reactive hydroxyl radical.

H2O2 generated in the extracellular medium or extracellular fluids appears to be the central player for pro-oxidant properties of AA at pharmacologic concentrations, achievable in cell culture experiments, and in vivo by intravenous administration. Extracellular H2O2 readily diffuses into cells; if not removed, it can lead to oxidative damage to proteins, lipids, and DNA. On the other hand, it is expected that AA, upon import through plasma membranes via sodium-dependent VitC transporters (SVCTs), can generate intracellular H2O2 directly by the same metals-catalyzed reactions described above. In accordance, AA cytotoxicity was observed in a number of studies in vitro and in vivo on models on cancer cells from different origins without adversely affecting normal cells [6–8]. Such cytotoxicity was also dependent on redox metal supply such as iron [9]. VitC antioxidant effects driven by its DHA form were also reported [10]. Yun et al. observed that VitC was oxidized to DHA in cell culture media lacking reducing agents, and was subsequently imported into human colon cancer cells harboring oncogenic KRAS or BRAF mutations by overexpressed GLUT1 glucose transporter. Following import, DHA is reduced to AA at the expense of glutathione (GSH) and NADPH. Increased DHA uptake leads to GSH oxidation, thus indirectly promoting endogenous ROS accumulation and specific inactivation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and consequently, impairing glycolysis and inducing cancer cell death [10].

Several studies addressed the question regarding VitC selective cytotoxicity toward cancer cell lines. Differential ability to metabolize H2O2 between normal and pancreatic cancer cells were shown to be determinant in AA effect on pancreatic cancer cells while sparing normal ones in vitro and in vivo [11]. In addition, a positive correlation between the sodium-dependent VitC transporter 2 (SVCT2) expression and AA cytotoxicity were reported in breast cancer cells, cholangiocarcinoma cell lines and patient-derived xenografts [12–14]. Interestingly, a recent study showed that non-small-cell lung cancer and glioblastoma cells are selectively sensitive to AA due to their altered redox-active iron metabolism, resulted from altered mitochondrial oxidative metabolism and increased levels of O2− and H2O2 [15]. The same team found similar benefits of pharmacological ascorbate in preclinical models of fibrosarcoma and liposarcoma [16]. Finally, different energy metabolisms between cancer and normal cells, known as the Warburg effect where cancer cells strongly depend on glycolysis for their energy and ATP production, render cancer cells far more vulnerable to glycolysis impairment by VitC than their normal counterparts [10,17,18].

Pharmacologic dose of AA enhanced chemosensitivity of ovarian cancer to carboplatin and paclitaxel and reduced toxicity of chemotherapy in mouse models [19]. AA also enhanced sensitivity to ionizing radiation by increasing H2O2-mediated DNA damage in pancreatic cancer model [20,21], and in prostate cancer cells while sparing normal cells from radiotoxicity [22]. Clinical studies revealed that pharmacologic doses of AA were well tolerated and increased the efficacy of conventional radio-chemotherapy in non-small-cell lung cancer and glioblastoma patients [15], and in pancreatic cancer patients [23].

These recent studies reflect a regained interest in VitC anticancer activity. However, VitC redox-based anticancer mechanisms warrant further investigation. Notably, which form of VitC exhibits the higher anticancer activity? Is this effect cell-type dependent? What are the factors that condition cellular sensitivity to VitC? What are the key intermediates (H2O2 or GSH oxidation) that lead to cell death? And which proteins or pathways are key targets of VitC-mediated oxidation? In this study we provide answers to these questions using breast cancer model.

2. Materials and methods

2.1. Cell culture

Triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and HTB-26, human umbilical vein endothelial cells (HUVEC) and human dermal fibroblasts (PCS-201-012) were purchased from American Type Culture Collection. Human mammary epithelial cells (HMEC) were purchased from Lonza. Additional breast cancer cell lines were obtained from the Translational Research Department of the Institut Curie (Paris, France). MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-549, HCC-1937, BT-20, MDA-MB-453, MDA-MB-134, MDA-MB-415, HUVEC and fibroblasts cells were grown in DMEM (Eurobio) supplemented with 10% FBS, 2 mM l-glutamine, 1X non-essential amino acids, 1 mM sodium pyruvate and 100 U/ml penicillin and 100 μg/ml streptomycin. HCC-1187, HCC-1954, T47D, HCC-1428 were grown in RPMI medium supplemented with 10% FBS, 2 mM l-glutamine 100 U/ml penicillin and 100 μg/ml streptomycin. HMEC were grown in mammary epithelial basal medium (MEBM) supplemented with MEGM SingleQuots (Lonza) (containing bovine pituitary extract, hydrocortisone, hEGF, insulin and gentamicin/amphotericin-B), 10% FBS and 100 U/ml penicillin and 100 μg/ml streptomycin. Cells are incubated in humidified atmosphere at 37 °C with 5% CO2 in air and were routinely checked for the absence

| Abbreviations | Definition |
|---------------|------------|
| AA | ascorbic acid |
| BrdU | 5-bromo-2-deoxy-uridine |
| DAVID | Database for Annotation, Visualization and Integrated Discovery |
| DHA | dehydroascorbic acid |
| DTT | dithiothreitol |
| GLUT1 | glucose transporter 1 |
| GO | Gene ontology |
| IPA | Ingenuity Pathways Analysis software |

| Abbreviations | Definition |
|---------------|------------|
| LC-MS/MS | liquid-chromatography tandem mass spectrometry |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| NAC | N-acetyl-L-cysteine |
| NEM | N-ethylmaleimide |
| PI | propidium iodide |
| SVCT | sodium-dependent vitamin C transporter |
| TCA | trichloroacetic acid |
| TNBC | triple-negative breast cancer |
| VitC | vitamin C |
of mycoplasma. Cell lines were authenticated using standard DNA microsatellite short tandem repeat (STR) method.

2.2. Drugs and reagents

L-ascorbic acid (AA), L-dehydroascorbic acid (DHA), N-ethylmaleimide (NEM), crystal violet, N-acetyl-l-cysteine (NAC), glutathione, DMSO, diethiothreitol (DTT), hydrogen peroxide (H2O2), catalase, diazide, trichloroacetic acid (TCA) and cycloheximide were purchased from Sigma-Aldrich. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), 5-bromo-2’-deoxy-uridine (BrdU) and propidium iodide (PI) were from Thermo Fisher Scientific. The following antibodies were used: anti-PRDX1 (Abcam), anti-GAPDH (CellSignaling Technology), FITC Mouse anti-BrdU (BD Biosciences).

2.3. ROS assessment, H2O2 detection and H2O2 quantification

General ROS were assessed using carboxy-H2DCFDA staining and a FACScan flow cytometer (Becton Dickinson) and data were analyzed using Flowjo software. For compartment-specific H2O2 detection, mammalian expression vectors encoding HyPer targeted to nucleus (with a nuclear localization signal), and mitochondria (with a mitochondrial matrix localization signal) were purchased from Evrogen. HyPer targeted to the cytosol with a nuclear export signal and HyPer targeted to the membrane using the membrane-targeting signal in protein GAP-4 were constructed in our laboratory. Cells were transfected with HyPer expressing vectors using jetPRIME reagents (Polyplus Transfection). Further experiments were performed 24 h after transfection. Analyses of oxidized and reduced forms of sensor by redox Western blot were performed according to Ref. [24]. H2O2 concentration in the medium was quantified using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific). The fluorescence was measured in a microplate reader (Victor3, PerkinElmer). H2O2 concentration in the growth medium (μM) was quantified using H2O2 standard calibration curves.

2.4. Quantitative redoxome analysis

Cells were subjected to different treatments and proteins were extracted. Purification of these proteins was performed according to a published protocol with slight modifications [25]. Protein digests were analyzed in triplicate with an Orbitrap Fusion Tribrid equipped with an EASY-Spray ion source. Label-free liquid-chromatography tandem mass spectrometry (LC-MS/MS) acquisition was performed. Peptides from MS/MS data were processed with Proteome Discoverer Software (v 2.1) using Sequest search node. All results were 1% FDR filtered before exporting. The resulting files were imported into Progenesis-Qi software (with a nuclear localization signal), and mitochondria (with a mitochondrial matrix localization signal) were purchased from Evrogen. HyPer targeted to the cytosol with a nuclear export signal and HyPer targeted to the membrane using the membrane-targeting signal in protein GAP-4 were constructed in our laboratory. Cells were transfected with HyPer expressing vectors using jetPRIME reagents (Polyplus Transfection). Further experiments were performed 24 h after transfection. Analyses of oxidized and reduced forms of sensor by redox Western blot were performed according to Ref. [24]. H2O2 concentration in the medium was quantified using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific). The fluorescence was measured in a microplate reader (Victor3, PerkinElmer). H2O2 concentration in the growth medium (μM) was quantified using H2O2 standard calibration curves.

2.5. BrdU incorporation and cell cycle analysis

BrdU incorporation and DNA staining with PI were performed using the acid denaturation method as described previously [27]. All samples were analyzed by a FACScan flow cytometer (Becton Dickinson) and data were analyzed using Flowjo software.

2.6. Translation studies

After different treatments, cells were incubated in growth media containing 100 μg/cycloheximide for 15 min at 37°C in order to stop ribosomal elongation. After being washed with ice-cold 1X PBS supplemented with 100 μg/ml cycloheximide, cells were scraped and harvested into ice-cold 1X PBS supplemented with 100 μg/ml cycloheximide and pelleted by centrifugation (3000 rpm for 5 min at 4°C). The pellets were resuspended in 400 μl of LSB buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 3 mM MgCl2, 1 mM DTT, 100 μg/ml of cycloheximide, and 100 U/ml of RNAsin) and lysed by adding 400 μl of LSB buffer containing 2.4% Triton X-100 and 0.5 M sucrose. The lysates were centrifuged (12000 g for 5 min at 4°C), and the supernatants were recovered and adjusted with additional 50 μl of LSB buffer containing NaCl and MgCl2 with quantities that enable final concentrations of 50 mM NaCl and 7 mM MgCl2. Then, supernatants were layered onto 15–50% sucrose gradients in LSB buffer, centrifuged (38,000 rpm for 2 h at 4°C) and 18 fractions were collected with a fraction collector. For nonpolysomal RNA (fractions 1 to 8, containing ribosomal RNAs present in 40S, 60S, and 80S ribosomal complexes, and free mRNAs) and polysomal RNA (fractions 9 to 18, containing mRNA bound to one ribosome), the optical density of these fractions (OD 254 nm) were determined.

2.7. Transcriptomic data analysis

Genes expression data were extracted from two publicly accessible transcriptomic datasets: NCI-60 CellMiner Database (https://discover.nci.nih.gov/cellminer/Database Version: 2.1) and affymetrix normalized data for breast cancer cell lines of the Institut Curie collection (http://microarrays.curie.fr/publications/recherche_translationnelle/plateforme_genomique/). Using NCI-60 CellMiner Database, each gene transcript Z-score (input HUGO name) and gene name were used as input identifier. The data file retrieved contained the average log2 intensity and Z-score of each gene expression in 60 cell lines. Using the Institut Curie database, gene mRNA expression levels (log2) for 29 breast cancer cell lines were retrieved.

2.8. Miscellaneous methods

MTT-based cell viability assay was performed as previously described [28]. For colony formation assays, cells were plated in 6-well plates in a density of 1000/well and treated under defined conditions and then further cultured for 14 days. Afterwards, colonies were fixed by ethanol, stained with crystal violet solution and counted using ImageJ software. For siRNA transfection, cells were transfected with 20 nM siRNA (ON-TARGET plus SMART pool siRNA or control siRNA, Dharmacon) using INTERFERin reagents (Polyplus Transfection). Further experiments were performed 48 h after transfection. Classical western blots and redox western blots were performed as described previously [24]. Total cellular glutathione levels (GSH + GSSG), GSSG (oxidized form) and GSH/GSSG ratios were assessed using GSH/GSSG Glo™ Assay (Promega). Luminescence was read using TriStar2 LB 942 Modular Monochromator Multimode Reader (Berthold technologies). Data were presented by GSH/GSSG ratios.

2.9. Statistical analysis

Statistical significance of each data set was analyzed using adequate
statistical tests available in the GraphPad Prism 7 software and specified in the body of manuscript and figure legends. Data were presented as the mean ± standard deviation (SD). Dose-response modeling, half-maximal inhibitory concentration (IC50) determination from MTT cell viability assays and Spearman's correlation analyses were also performed using the GraphPad Prism 7 software (GraphPad Software, Inc). Wherever possible, exact P values are given and P < 0.05 were considered statistically significant.

3. Results

3.1. AA shows higher cytotoxicity toward breast cancer cells than DHA without affecting noncancerous cells

A panel of 7 TNBC cell lines was exposed to increasing concentrations of AA and DHA. MTT assays showed that TNBC cells displayed different sensitivity to AA treatment for 24 h (Fig. 1A). At pharmacologic concentrations, MDA-MB-231 cells, among others (HCC-1187, BT549, MDA-MB-468, HCC-1937 and BT20), were highly sensitive to AA ranging from 7 mM to 10 mM (~4–20% viability at 10 mM AA); while MDA-MB-436 showed more resistance (~70% viability at 10 mM AA). Less cytotoxicity was observed with DHA for all TNBC cells in the same treatment conditions. Only 3 cell lines (HCC-1187, BT20 and MDA-MB-231) were sensitive to 10 mM DHA treatment for 24 h (~7–40% viability) (Fig. 1B). Upon AA and DHA treatments for 24 h, MTT assays and clonogenic assay confirmed that VitC-induced cytotoxicity was associated with a loss of the ability to form colonies and that AA displayed stronger cytotoxicity than DHA (Fig. 1C). In addition, we determined the sensitivity of 6 non-TNBC cell lines to AA treatment for 24 h (Fig. 1D). Five of them (MDA-MB-134, T47D, HCC-1428, MDA-MB-415 and MDA-MB-453) were sensitive to 10 mM AA treatment (~5–35% viability) while HCC-1954 showed more resistance (~80% viability). Finally, noncancerous cell lines including HMEC, human dermal fibroblasts and HUVEC showed a high survival rate even at 10 mM AA treatment (60–80%) (Fig. 1E).

3.2. H2O2 generation and GSH oxidation underlie AA-induced cytotoxicity while GSH oxidation plays a partial role in DHA-induced lower cytotoxicity

In order to understand the mechanism of action of AA and DHA, we used MDA-MB-231 cells, one representative TNBC cell line that is commonly studied in literature, to evaluate the redox alteration induced by VitC treatments. For this purpose, two concentrations of VitC were further used, the non-cytotoxic 2.5 mM and the cytotoxic 10 mM. Since DHA was shown to be responsible for GSH oxidation upon increased uptake through the glucose transporter GLUT1 in colorectal cancer model [10], we first determined the reduced and oxidized levels of this main cellular antioxidant after AA and DHA treatments in MDA-MB-231 cells. As shown in Fig. 2A, a significant decrease in GSH/GSSG ratios, indicating GSH oxidation, is observed after 2 h treatment with 10 mM AA or DHA but not with 2.5 mM Next, we performed a general ROS assessment using carboxy-H2DCFDA. A 2-fold increase in fluorescence intensity was detected upon treatment for 4 h with 10 mM but not with 2.5 mM AA (Fig. 2B). Co-treatment with 10 mM AA and either catalase or GSH abolished the increase in the fluorescence intensity.

Fig. 1. Sensitivity of TNBC, non-TNBC and noncancerous cells toward AA and DHA. (A-B) Seven TNBC cell lines were treated with AA (A) or DHA (B) ranging from 0 to 10 mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay for each cell line. Data are means ± SD of at least 6 independent experiments. Statistical significance is assessed by two-way ANOVA with Sidak’s multiple comparisons test. (C) MDA-MB-231 cells were treated with AA or DHA for 24 h. Cell viability (%) relative to non-treated condition was measured by MTT assay (left panel). Data are means ± SD of at least 6 independent experiments. Representative images of colonies formation of MDA-MB-231 cells after AA or DHA treatments for 24 h are shown (right panel). (D) Six non-TNBC cells were treated with AA ranging from 0 to 10 mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay. Data are means ± SD of at least 6 independent experiments. Statistical significance is assessed by two-way ANOVA with Sidak’s multiple comparisons test. (E) HMEC, normal human dermal fibroblasts and HUVEC were treated with AA ranging from 0 to 10 mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay for each cell line. Data are means ± SD of 4 independent experiments. Statistical significance is assessed by ordinary two-way ANOVA with Tukey’s multiple comparisons test. ****, P < 0.0001.
Fig. 2. Glutathione oxidation and ROS generation in response to AA and DHA treatments in MDA-MB-231 cells. (A) GSH and GSSG quantities were assessed in non-treated cells and cells treated with 2.5 or 10 mM AA or DHA for ½ hour and 2 h. Treatment with 250 µM diamide for 10 min was used as a positive control (PC). GSH/GSSG ratio value in non-treated cells is set as 1 and relative GSH/GSSG ratios calculated in treated conditions are represented as means ± SD of 4 independent experiments. Statistical significance is assessed by ordinary one-way ANOVA with Tukey’s multiple comparisons test. (B) General intracellular ROS was assessed by flow cytometry using carboxy-H₂DCFDA probes in non-treated cells (NT), cells treated with 2.5 or 10 mM AA or DHA for 4 h (upper panel), cells treated with 10 mM AA, 10 mM AA plus 2000 U/ml catalase or 10 mM AA plus 10 mM GSH (lower panel). Treatment with 100 mM H₂O₂ for 20 min was used as a positive control (PC). Mean fluorescence value in non-treated MDA-MB-231 cells is set as 1 and relative fluorescence intensity is represented. Data are means ± SD of 4 independent experiments. Statistical significance is assessed by two-way ANOVA with Tukey’s multiple comparisons test. ***, P < 0.0001; **, P < 0.01; *, P < 0.05.

We then questioned the link between these redox alterations and ViTc cytotoxicity. Noticeably, AA-induced cytotoxicity in MDA-MB-231 cells could be totally or largely suppressed by the presence of either catalase, NAC or GSH (Fig. 2B). NAC serves as a prodrug to cysteine which is a precursor to GSH. On the other hand, DHA-induced cell death was not rescued by catalase, while partially by GSH or NAC, with mean cell viability 58% and 61% respectively. These observations indicate the role of H₂O₂ generation and GSH oxidation in AA cytotoxicity and a partial implication of GSH oxidation in DHA cytotoxicity.

To further verify the generation of H₂O₂ in AA-treated condition, we used Amplex-Red Kit to measure H₂O₂ concentration in the medium. After 10 mM AA treatment for 5 min, ½ hour and 2 h, H₂O₂ concentrations in the medium with or without MDA-MB-231 cells increased more than 20 times (Fig. 3A). Furthermore, the co-treatment by AA and catalase abolished H₂O₂ accumulation, validating the extracellular generation of H₂O₂ by AA. Next, we used genetically encoded HyPer sensors addressed to several cellular compartments in MDA-MB-231 cells to determine whether H₂O₂ accumulated intracellularly in one or more cellular compartments. HyPer sensors specifically react with H₂O₂ [29,30]. Cytoplasm-localized HyPer oxidation was visible in presence of 10 mM AA for 5 min, ½ hour and 2 h, indicating a continuous H₂O₂ accumulation in the cytoplasm of the cells upon AA treatment (Fig. 3B). The same results were obtained with nucleus-, mitochondrial matrix- and membrane-targeted HyPer. Furthermore, co-treatment with AA and catalase abolished the oxidation of HyPer. Finally, the redox states of two compartment-specific antioxidant proteins, cytoplasmic PRDX1 and mitochondrial PRDX3, were analyzed by redox Western blot. Cytotoxic dose of AA (10 mM) increased PRDX3 oxidation (50–60% dimer) and PRDX1 oxidation (~10% dimer) after 5 min, ½ hour and 2 h of treatment, indicating mitochondrial and cytosolic H₂O₂ accumulation (Fig. 3C). These data are in agreement with an important role of H₂O₂ in AA-induced cytotoxicity.

3.3. AA treatment alters the redox state of cysteine-containing proteins

Our observations described above linked AA cytotoxicity to extracellular and intracellular H₂O₂ accumulation and showed the redox state alteration of some cysteine-containing antioxidants upon AA treatment. As many proteins with highly reactive cysteine residues are implicated in different critical pathways and could be impacted by H₂O₂, we decided to examine the alterations of the redoxome, the oxidized proteome of cysteine-containing proteins, by redox mass spectrometry approach [31,32]. Using a biotin switch approach that allows the enrichment of proteins containing oxidized thiols [25], we compared the redoxome of non-treated and treated (10 mM AA, ½ hour) MDA-MB-231 cells in two independent biological replicates, each with three technical replicates (Supplementary Fig. 1). Upon short AA treatment, we expected to identify early events in cellular response to AA that might be linked to AA-induced cell death.

Quantitative proteomic analysis by LC-MS/MS allowed the identification of 2910 cysteine-containing proteins. Among them, 203 proteins (6.97%) were commonly identified in both biological experiments and exhibited a significant change in cysteine oxidation levels between non-treated and treated cells (over 1.5-fold in at least one of the two biological experiments with P < 0.05) (Supplementary Table 1). 38.42% of these proteins were more oxidized while 61.58% were more reduced in 10 mM AA-treated cells compared to the non-treated condition. The high proportion of more reduced proteins following AA treatment is intriguing but could be explained by the fact that intracellularly AA could not only generate H₂O₂ but also act as a conventional reducing agent, generating both oxidized and reduced proteins upon AA treatment. Compartment-specific redox response could also be taken into account. Proteins in some compartments could be more oxidized while those in other compartments could be more reduced through antioxidant system response against the AA-induced H₂O₂ and oxidative stress, thus protecting some important cellular signaling pathways and proteins from oxidation.

As expected, antioxidant enzymes including glutathione S-transferase Mu 3 (GSTM3), γ-glutamylcyclotransferase (GGCT) and PRDX1 were among the identified oxidized targets of AA treatment (Supplementary Table 1), compromising antioxidant capacity. On the other hand, proteins belonging to the glycolysis and gluconeogenesis pathway (PGM, PGK1), and tricarboxylic acid cycle (ACO1, DLAT, FADS2), exhibited also a significant increase in oxidation upon AA treatment. Thus, energetic metabolism enzymes were also among the targets of AA, in accordance with the energetic crisis and metabolic alterations described in other studies [33]. Interestingly, several proteins implicated in DNA and RNA metabolism as well as in protein metabolism were oxidized in treated cells, including chromosome-associated kinesin KIF4A (accession number O95239), histone-binding protein RBBP4 (Q90928), ATP-dependent RNA helicase DHX8 (Q14562), U5 small nuclear ribonucleoprotein 40-kDa protein (Q9617), tRNA-splicing ligase RtcB homolog (Q9Y310), 26S proteasome non-ATPase regulatory subunit 3 (O43242), Cullin-4A (Q13619), E3 ubiquitin-protein ligase RING2 (Q99496), E3 ubiquitin-protein ligase UBR4 (Q5T457), E3 ubiquitin-protein ligase XIAP (P98170), and E3 SUMO-protein ligase RanBP2 (P49792) (Supplementary Table 1). These data indicate that AA leads to the oxidation of thiol-containing proteins implicated in several essential cellular processes such as energy production, nucleic acid and protein metabolisms.

IPA software for enrichment analysis of these 203 proteins differentially oxidized between AA-treated and non-treated conditions revealed that glucocorticoid receptor signaling and EIF2 signaling pathways were among the top significant canonical pathways (Fig. 4A). The top five significantly enriched molecular and cellular pathways included cellular assembly and organization, cellular function and maintenance, RNA post-transcriptional modification, molecular transport and RNA trafficking (Fig. 4A). These proteins’ main networks were dominated by RNA post-transcriptional modification, cancer, cell death and survival (Fig. 4A). Moreover, protein classification according to their GO biological processes in DAVID database fall into categories of cell-cell adhesion, RNA processing, translational initiation, viral transcription, and cell proliferation, among others (Fig. 4B). Taken together, redoxome data seem to point to the possible effect of AA treatment on DNA replication and transcription/translating, among other pathways.
suggesting that H2O2 production is causal in the inhibition of DNA replication.

To support these data, cells were first labeled with BrdU, and then BrdU incorporation was observed after 2h of AA treatment, indicating which can be incorporated into the DNA during replication. BrdU staining thus allows to follow newly synthesized DNA together with 3.4. S-phase of cell cycle is affected by AA treatment

As a first attempt, we performed cell cycle analysis on MDA-MB-231 cells upon AA treatment using BrdU. BrdU is a thymidine analogue that can be incorporated into the DNA during replication. BrdU staining thus allows to follow newly synthesized DNA together with total DNA staining by PI to measure total DNA content and assign the cells to the various stages of the cell cycle. Cells were left non-treated or treated with 10 mM AA for 2h. Then, at various time points of post-treatment recovery (from 0 to 24h), cells were pulse-labeled with BrdU followed by PI staining and FACS analysis. A significant decrease in BrdU incorporation was observed after 2h of AA treatment, indicating an S-phase arrest when compared to non-treated cells (Fig. 5A and B). To support these data, cells were first labeled with BrdU, and then treated or not with 10 mM AA for 2h before being analyzed by FACS at various time points after post-treatment recovery. Cells subjected to AA treatment showed an immediate and prolonged S-phase delay (Fig. 5C). Moreover, catalase efficiently prevented S-phase slowdown in both conditions of BrdU pulse, post and prior AA treatment (Fig. 5A–C), suggesting that H2O2 production is causal in the inhibition of DNA replication. Taken together, these observations points to the possibility that the inhibition of DNA replication is one of the causes of AA cytotoxicity.

3.5. Translation inhibition in response to AA treatment

We next performed polysome profiling to monitor translation activity of mRNA in MDA-MB-231 cells upon AA treatment. Cellular RNAs were extracted and fractioned in a 15-50% sucrose gradient. When comparing nonpolysomal and polysomal RNA quantities between non-treated cells and cells treated with 10 mM AA for 2h, a significant decrease in polysomal RNA (62 ± 5% vs 44 ± 2%) accompanied with a significant increase in nonpolysomal RNA (38 ± 5% vs 56 ± 2%) occurred, reflecting a decrease of cellular translation activity upon AA treatment (Fig. 6A and B). Moreover, adding catalase (2000 U/ml) that rescued cell viability rescued partially the cellular translation activity as seen for polysomal RNA (44 ± 2% in AA-treated cells vs 53 ± 6% in AA plus catalase-treated cells) and for nonpolysomal RNA (38 ± 5% vs 47 ± 6%) (Fig. 6A and B). Taken together, these data suggest that the AA-induced inhibitory effect on mRNA translation contributes to AA cytotoxicity.

3.6. H2O2 scavenging system including PRDX1 is linked to variable cellular sensitivity to AA

The different sensitivity to AA among TNBC and non-TNBC cells prompted us to identify gene and protein expressions that correlate with AA anticancer activity. Pattern comparison using the NCI-60 CellMiner web tool [34,35] was performed to assess the correlation between gene expression and AA cytotoxicity. Significant negative Pearson's correlations (meaning that the more a gene is expressed, the more cells are resistant to AA) were defined at $r < -0.334$ based on a minimum of 35 informative cell lines, and $P$ value $< 0.05$ in the absence of multiple comparisons. This analysis allowed us to identify genes with transcript levels correlated negatively and significantly with AA cytotoxicity (Supplementary Table 2). PTGR1 had the highest significant correlation value ($r = -0.608$, $P = 0$) and was already highlighted in our earlier work as a predictive biomarker for resistance of breast cancer cell lines to auranofin/VitC combinatorial cytotoxicity [28]. For AA alone, expressions of some antioxidant genes such as TXNRD1 ($r = -0.401$, $P = 1.624 \times 10^{-3}$) and PRDX1 ($r = -0.384$, $P = 2.678 \times 10^{-3}$) also correlated negatively with AA cytotoxicity.

We performed a pathway analysis using the IPA software for the 246 genes. NRF2-mediated oxidative stress response was the first significant canonical pathway enriched (Supplementary Fig. 2A). Top statistically significant molecular and cellular pathways for these genes included cellular movement and cell death and survival, among others. Finally, the top networks of these genes included cancer, cell death and survival and carbohydrate metabolism. Protein classification according to their GO biological processes in DAVID database highlighted a significant association with signal transduction, oxidation-reduction process, and response to oxidative stress, among others (Supplementary Fig. 2B). All these data directed us to conclude that oxidative stress response genes play a role in the resistance of cancer cells to H2O2-mediated cytotoxicity of AA.

We wanted to ascertain that, for these genes, the predicted negative correlation of their expression with AA activity according to NCI-60 database are indeed valid on breast cancer cell lines. We thus calculated IC50 of AA on 13 breast cancer cell lines (Supplementary Fig. 3) and correlated them with the retrieved gene expression data from the Institut Curie database. Fig. 7A shows PRDX1 gene expression (mRNA) distribution of 29 breast cancer cell lines. A correlation between AA activity ($\log_{10}IC50$) and PRDX1 expression levels ($\log_{2}$) was statistically significant and valid for most of the breast cancer cell lines studied (Spearman's correlation $r = 0.5769$, $P = 0.0425$) (Fig. 7B and C). By knocking down PRDX1 gene, the highly resistant HCC-1954 became significantly more sensitive to 10 mM AA, MDA-MB-436 cells became significantly more sensitive to 5 or 10 mM AA (Fig. 7D and E), and MDA-MB-231 cells became significantly more sensitive to 2.5 mM AA (Fig. 7F). Consistently, we previously showed that PRDX1 knockdown sensitizes HeLa and A549 cancer cells toward ROS-generating anticancer molecules [24,36]. More recently, other researchers reported inhibitory effect of PRDX1-knockout on growth of mammary tumor in mouse model, enhancing VitC cytotoxicity [37]. Finally, NCI-60 data also indicate that lung cancer cells that are mostly resistant to AA have high PRDX1 expression (Supplementary Fig. 4). Further experiments on larger panel of cells in each cancer type are needed for achieve firm conclusions on the predictive value of PRDX1 expression.

4. Discussion

Anticancer effect of VitC at pharmacologic concentrations has been largely attributed to H2O2 extracellular generation from AA [4,6–8,38,39]. However, one study reported that VitC selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH via DHA [10]. Here we showed that AA displayed much higher cytotoxicity than DHA in 13 breast cancer cell lines. Normal cells including HMEC, human dermal fibroblasts and HUVEC were much less affected by AA.
Fig. 4. Pathway, function and network analysis of the differentially oxidized cysteine-containing proteins identified by “redoxome” upon AA treatment. The alterations of the oxidized proteome of cysteine-containing proteins, after 10 mM AA treatment for ½ hour in MDA-MB-231 cells were analyzed by mass spectrometry. 203 differentially oxidized proteins with \( P < 0.05 \) and a fold change over 1.5 in at least one of the two biological experiments were identified between AA-treated and non-treated cells. (A) Significantly altered cysteine-containing proteins were mapped by the IPA analysis software. The top 5 significantly associated canonical pathways, molecular and cellular functions and networks of these proteins are represented. (B) Altered proteins were classified according to their GO biological process pathways in DAVID database. The top significantly (Fisher’s modified test) associated biological processes are represented. **, \( P < 0.01 \); *, \( P < 0.05 \).
A. +/- AA treatment → Recovery → BrdU for 1 h → PI staining → FACS

Post-AA treatment 0 h 6 h 24 h

NT
S 42.0%
G0-G1 37.6% G2-M 20.5%

AA
S 17.1%
G0-G1 58.6% G2-M 24.1%

AA + catalase
S 39.0%
G0-G1 41.2% G2-M 19.8%

FITC anti-BrdU
DNA content (PI)

B

% of cells
AA catalase - + + 0 h

G0-G1
S
G2-M

C. BrdU for 1 h → +/- AA treatment → Recovery → PI staining → FACS

Post-AA treatment 0 h 6 h 24 h

NT

AA

AA + catalase

FITC anti-BrdU
DNA content (PI)

(caption on next page)
treatment. While most of breast cancer cell lines were sensitive to AA similar to MDA-MB-231 cells, some cell lines, such as HCC-1954 and MDA-MB-436, were more resistant. AA-induced cytotoxicity toward MDA-MB-231 cells was entirely linked to extracellular H$_2$O$_2$ generation and intracellular accumulation in different compartments together with GSH oxidation.

Since H$_2$O$_2$ is the main player in AA cytotoxicity, we analyzed redoxome in MDA-MB-231 cells in order to reveal a general oxidation spectrum of cysteine-containing proteins in response to AA. The short-time AA treatment (½ hour) unlikely affects basal protein abundance and therefore is less likely to bias protein oxidation data. Indeed, Western blot for several randomly selected individual proteins that showed a significant change in oxidation/reduction state of cysteines following AA treatments indicated no change in total protein abundance under the same condition as used in redoxome study (data not shown). As expected, AA oxidizes antioxidant proteins such as PRDX1.

Fig. 5. Effect AA treatment on cell cycles of MDA-MB-231 cells. (A) Non-treated (NT) cells, cells treated for 2 h with 10 mM AA, 10 mM AA plus 2000 U/ml catalase were released in fresh medium. At various time points of post-treatment recovery (from 0 to 24 h), these cells were stained with BrdU for 1 h followed by PI staining and FACS analysis. Dot plots of samples from 0, 6 and 24 h post-treatment recovery are presented with values of the percentages (%) of the population in each phase of cell cycle (G0-G1, S, G2-M). (B) Histogram shows the percentages (%) of cells in G0-G1, S, G2-M phases at 0 h post-AA treatment as means ± SD calculated from 3 independent experiments. Statistical significance is assessed by one-way ANOVA with Tukey's multiple comparisons test. *, $P < 0.05$. (C) MDA-MB-231 cells were labeled with BrdU for 1 h and then subjected to three treatment conditions for 2 h: non-treatment (NT), treated with 10 mM AA, or 10 mM AA plus 2000 U/ml catalase. Cells were then analyzed by flow cytometry after PI staining at different time points during recovery in growth media (0, 6 or 24 h). Representative graphs of at least 3 experiments are shown.

Fig. 6. Effect AA treatment on polysome gradient profiles of MDA-MB-231 cells. (A) Non-treated (NT) cells, cells treated for 2 h with 10 mM AA, 10 mM AA plus 2000 U/ml catalase were incubated for 15 min with cycloheximide to stop ribosomal elongation. Cellular RNA was extracted and fractioned in a 15–50% sucrose gradient. Optical density profiles (OD 254 nm) of polysome gradient profiles are shown, and non-polysomal RNA corresponding to fractions 1 to 8 (containing ribosomal RNAs present in 40S, 60S, and 80S ribosomal complexes and free mRNAs) and polysomal RNA corresponding to fractions 9 to 18 (containing mRNAs bound to more than one ribosome) are indicated. (B) The areas under the curve (AUC) of the optical density profiles of non-polysomal and polysomal RNA were measured, the percentage of non-polysomal or polysomal RNA relative to total was then calculated. Quantifications are represented in graphs as means ± SD of 3 independent experiments. Statistical significance is assessed by ordinary one-way ANOVA with Tukey's multiple comparisons test. **, $P < 0.01$; *, $P < 0.05$. 

N. El Banna, et al. Redox Biology 26 (2019) 101290
Fig. 7. PRDX1 expression and its link to breast cancer cellular response to AA. (A) PRDX1 mRNA expression patterns in log$_2$ values in 29 breast cancer cells retrieved from publicly available transcriptomic datasets of the Institut Curie breast cancer cell lines. Mean and median values are shown as solid and dashed lines, respectively. (B) Spearman's correlation analysis corresponding to PRDX1 mRNA expression vs IC50 for AA on 13 breast cancer cell lines. IC50 values were calculated from MTT assays for cell viability. Spearman's correlation was performed using GraphPad software. The 7 TNBC cell lines are indicated by green symbols and the 6 non-TNBC cell lines by purple symbols. The best-fit line is in solid orange line and the 95% confidence bands of the best-fit line are indicated in blue lines. Mathematical parameters are represented next to the graphs. (C) logIC50 of AA for breast cancer cell lines and their PRDX1 mRNA expression in log2 values. (D-E-F) MTT assay on HCC-1954, MDA-MB-436 and MDA-MB231 cells transiently transfected with PRDX1 specific siRNA or control siRNA for 48 h followed by treatments with different concentrations of AA for 24 h. The insert is Western blot to verify efficiency of PRDX1 knockdown in siRNA transfected cells. Statistical significance is assessed by two-way ANOVA with Sidak's multiple comparisons test. ****, $P < 0.0001$. 

N. El Banna, et al. Redox Biology 26 (2019) 101290
and GGCT, very probably affecting the thioredoxin and glutathione scavenging systems. Furthermore, AA alters the redox state of many proteins implicated in the metabolic process, providing a rational explanation for a set of previously reported data that AA induced metabolic alterations, impairing glycolysis [10], pentose phosphate pathway, glycolysis and tricarboxylic acid cycle [18], impairing the Warburg metabolism and downregulating glucose transporters and pyruvate kinase M2 in cancer cells [33].

Several proteins involved in RNA metabolism and related pathways such as rRNA processing and translational initiation were significantly enriched in redoxome data upon AA treatment. Consistently, we showed a strong inhibitory effect of AA on mRNA translation in MDA-MB-231 cells, indicating that mRNA translation inhibition is one of the possible mechanisms responsible for oxidative stress-based AA cytotoxicity. This is in accordance with the fact that cells globally down-regulate translation as quick adaptive response to stress [40]. In fact, cells resort to translational reprogramming toward selective translation of mRNAs encoding vital proteins, involved in survival and stress recovery, in an attempt to alleviate cellular burden under unfavorable conditions [41]. It is worth noting that since recognizing the important role played by deregulated translation in carcinogenesis [42], the repression or blockage of protein synthesis has gained a significant interest as a promising anticancer strategy [43,44]. Similarly, a set of proteins implicated in DNA metabolism and related cell proliferation pathway were found among the proteins with oxidized cysteine upon AA treatment. Indeed, cell cycle of MDA-MB-231 cells was impaired upon AA treatment for 2 h, suggesting potential involvement of DNA replication inhibition in AA cytotoxicity. It is shown that AA, via H2O2 generation, induces time- and concentration-dependent genotoxic stress and DNA damage and activates the ataxia telangiectasia mutated (ATM)/adenosine monophosphate-activated protein kinase (AMPK) pathway, all of which inhibit the mammalian target of rapamycin (mTOR) signaling pathway connected to cell proliferation, inducing cell death in ovarian cancer cells [19]. On the other hand, a direct impact of VitC and vitamin K3 combination on ribonucleotide reductase (RNR) was observed [45]. RNR activity was directly inhibited by the H2O2 generated along with the limited electron supply upon thioredoxin and glutathione oxidation by the combination of the two molecules. RNR is essential for de novo production of deoxyribonucleotides that is highly needed in cancer cells, thus RNR could be the link between VitC, DNA replication impairment and cancer cell death [45].

The mechanism by which VitC kills cancer cells while sparing normal cells is not entirely clear. It could be linked to a differential ability to metabolize H2O2 between normal and cancer cells [11], differential SVCT2 expression [14], or to cancer cells altered redox-active iron metabolism [15]. Our redoxome data and bioinformatics analysis indicate that AA-generated H2O2 can target multiple pathways at the same time, which might be particularly deleterious for cancer cells that strongly rely on antioxidants and metabolic reprogramming for survival, contributing cytotoxic selectivity of AA in cancer vs normal cells.

Our bioinformatics analysis also revealed that proteins belonging to the antioxidant system or NRF2-mediated oxidative stress response are linked to variable cellular sensitivity to AA (Supplementary Fig. 2A). Precisely, PRDX1 gene expression correlated significantly with the response of breast cancer cell lines to AA, as cells with higher PRDX1 expression were more resistant to AA, and PRDX1 knockdown enhanced cellular sensitivity to AA. PRDX1 is a key antioxidant that is directly involved in H2O2 elimination, thus has a protective activity against AA-generated H2O2 and could indeed be linked to AA resistance. PRDX1 prediction value to AA treatment outcome warrants further validation in pre-clinical and clinical studies.

In summary, combined with previously reported data in the literature, this work provides insights on differential breast cancer cell line response toward AA and DHA treatments (Fig. 8). We first showed an extracellular generation of H2O2 by AA, but also an intracellular accumulation of H2O2. Intracellular H2O2 can be transported from the extracellular medium by aquaporins or by passive diffusion across plasma cellular membranes [46] but also generated by intracellular AA upon import through SVCTs (mainly SVCT2) [47]. Although in breast cancer cells, AA may not be imported by SVCT2, but only to mitochondria via mitochondrial SVCT2 (mitSVCT2), AA can be oxidized extracellularly to DHA and then imported through glucose transporters to be reduced by GSH-dependent mechanisms to AA intracellularly [48], consuming intracellular GSH [49,50]. AA treatment was cytotoxic toward most of breast cancer cells tested and its higher cytotoxicity compared to DHA was mainly linked to H2O2 generation. We identified that proteins involved in DNA replication, cell cycle progression and translations are among the principal targets of AA-induced cysteine redox alterations and could be linked to AA-induced cytotoxicity.

Clinical data demonstrate that plasma VitC concentrations even greater than 10 mM are achievable in humans without causing apparent adverse effects [51,52], and that pharmacological AA are well tolerated by patients and can increase the efficacy of conventional radiotherapy and chemotherapy [15,23]. In our study, such AA concentrations were cytotoxic toward most of breast cancer cell lines without severely affecting normal cells, suggesting that VitC and VitC-based rational drug combinations could be novel therapeutic opportunities for triple-negative breast cancer and other cancers with similar redox properties.

Financial support

This work was supported by the CNRS, the Institut Curie, the Institut National du Cancer SIRIC grant (INCa-DGOS-4645 to MEH), la Fondation ARC grant (PJA 20151203330 to MEH). NEB is supported by a postdoctoral fellowship from the Ligue Nationale Contre le Cancer and Crédit Agricole île de France Méécnac. LV is supported by INSERM.
Disclosure of potential conflicts of interest

The authors disclose on potential conflicts of interest.

Acknowledgements

We thank Fabien Reyal and Alice Pinheiro for kindly providing us some of the breast cancer cell lines used. We also thank Hélène Malka-Mahieu, Pierre-Marie Girard, Charlène Lasgi and Marie-Noëlle Soler for advice and technical assistance.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2019.101290.

References

[1] C. Gorrini, L.S. Harris, T.W. Mak, Modulation of oxidative stress as an anticancer strategy, Nat. Rev. Drug Discov. 12 (12) (2013) 931–947.
[2] D. Trachootham, J. Alexandre, P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 (7) (2009) 579–591.
[3] L. Chaiswing, W.H. St Clair, D.K. St Clair, Redox paradox: a novel approach to understanding and gaps in knowledge, Front Oncol. 7 (2017) 74.
[4] J. Yun, J.J. Cullen, G.R. Buettner, Ascorbic acid: chemistry, biology and the treatment of cancer, Biochim. Biophys. Acta 1826 (2) (2012) 434–457.
[5] C.J. Michels, B. Frei, Myths, artifacts, and fatal flaws: identifying limitations and opportunities in vitamin C research, Nutrients 5 (12) (2013) 5165–5192.
[6] Q. Chen, M.G. Espey, A.Y. Sun, J.H. Lee, M.C. Krishna, E. Shacter, P.L. Choyke, C. Pooput, K.L. Kirk, G.R. Buettner, et al., Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo, Proc. Natl. Acad. Sci. U.S.A. 104 (21) (2007) 8749–8754.
[7] Q. Chen, M.G. Espey, A.Y. Sun, C. Pooput, K.L. Kirk, M.C. Krishna, D.B. Rhos, J. Drisko, M. Levine, Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Proc. Natl. Acad. Sci. U.S.A. 105 (32) (2008) 11015–11019.
[8] M. Levine, M.G. Espey, Q. Chen, Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment, Free Radic. Biol. Med. 47 (1) (2009) 27–29.
[9] K.E. Brandt, K.C. Falls, J.D. Schoenfeld, S.N. Rodman, Z. Gu, F. Zhan, J.J. Cullen, B.A. Wagner, G.R. Buettner, B.G. Allen, et al., Augmentation of intracellular iron and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination therapy targeting triple-negative breast cancer, J Natl Cancer Inst. 111 (6) (2019) 597–608.
[10] A.J. Meyer, T.P. Dick, Fluorescent protein-based redox probes, Antioxid Redox Signal 13 (5) (2010) 621–650.
[11] V.V. Belousov, A.F. Fradkov, A.Y. Lukyanov, D.B. Staroverov, K.S. Shakhbazov, A.V. Tereskh, S. Lukyanov, et al., Quantum dot-based redox reporter for intracellular hydrogen peroxide, Nat. Methods 3 (4) (2006) 281–286.
[12] Y.M. Go, D.P. Jones, The redox proteome, J. Biol. Chem. 288 (37) (2013) 26512–26520.
[13] Y.M. Go, J.D. Chandler, D.P. Jones, The cytochrome proteome, Free Radic. Biol. Med. 84 (2015) 227–245.
[14] O. Aguilera, M. Munoz-Sagastibelza, B. Torrejon, A. Borroto-Palacios, L. Del Puerto-Nevado, J. Martinez-Useos, M. Rodriguez-Remirez, S. Zazo, E. Garcia, M. Fraga, et al., Vitamin C uncovers heat shock protein HSP27 as a novel therapeutic target in triple negative breast cancer, Oncotarget 7 (30) (2016) 47954–47965.
[15] W.C. Reinhold, M. Sunshine, H. Li, S. Varma, K.W. Kohn, J. Morris, J. Dorobosh, Y. Pommier, CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NGC-60 cell line set, Cancer Res. 72 (14) (2012) 3499–3511.
[16] U.S. Shanakavaram, S. Varma, D. Kane, M. Sunshine, K.K. Chary, W.C. Reinhold, Y. Pommier, CellMiner: a relational database and query tool for the NGC-60 cancer cell lines, BMC Genomics 10 (2009) 277.
[17] T. He, A. Banach-Latapy, L. Vernis, M. Dardalhon, R. Chane , M.E. Huang, Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals, Carcinogenesis 34 (3) (2013) 760–769.
[18] M. Bajor, A.O. Zych, A. Gracezy-Jarzynka, A. Muchowicz, M. Firczuk, L. Trzeciak, A. Zagozdzon, et al., Targeting peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals, Carcinogenesis 34 (3) (2013) 760–769.
[19] M. Bajor, A.O. Zych, A. Gracezy-Jarzynka, A. Muchowicz, M. Firczuk, L. Trzeciak, A. Zagozdzon, et al., Targeting peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals, Carcinogenesis 34 (3) (2013) 760–769.
[20] D. Silvera, S.C. Formenti, R.J. Schneider, Interdisciplinary Rev RNA 5 (3) (2014) 301–315.
[21] D. Silvera, S.C. Formenti, R.J. Schneider, Translational control in cancer, Nat. Rev. Genet. 12 (12) (2011) 833–845.
[22] D. Silvera, S.C. Formenti, R.J. Schneider, Translational control in cancer, Nat. Rev. Cancer 10 (4) (2010) 254–266.
[23] L.M. Lindqvist, I. Vikstrom, J.M. Chambers, K. McArthur, M. Anderson, K.J. Lennard, L. Happle, L. Cluze, R.W. Johnstone, A.W. Roberts, et al., Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor, Cell Death Dis. 3 (2012) e409.
[24] M. Bhat, N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier, I. Topisirovic, Targeting the translation machinery in cancer, Nat. Rev. Drug Discov. 14 (4) (2015) 261–278.
[25] X. Ren, S.M. Santoso, L. Coppel, F.T. Ogata, J. Lu, A. Holmgren, The combination of ascorbate and menadione causes cancer cell death by oxidative stress and re-activation of free radicals, Free Radic. Biol. Med. 134 (2019) 350–358.
[26] G.P. Binnert, J.K. Schjoerring, T.P. Jahn, Membrane transport of hydrogen peroxide, Biochim. Biophys. Acta 1758 (8) (2006) 994–1003.
[27] H. Tsukaguchi, T. Tokui, B. Mackenzie, U.V. Berger, X.Z. Chen, Y. Wang, T. He, H. El Banna, T. Yu, P. Chen, S. Williamson, P.C. Violet, Z. Pesnetko, A.K. Godwin, F. Fan, et al., High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis and a phase I/IIa study, Sci. Rep. 7 (1) (2017) 17188.
[28] T. He, E. Hatem, L. Vernis, M. Le, M.E. Huang, PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug, Exp. Clin. Cancer Res. 34 (2015) 152.
[29] B.A. Wagner, G.R. Buettner, A.M. Button, et al., Pharmacological ascorbate radiosensitizes pancreatic cancer, Cancer Res. 75 (16) (2015) 3314–3326.
[30] J. Du, S.M. Martin, M. Levine, B.A. Wagner, R.G. Buettner, S.H. Wang, A.F. Taghiyev, C. Du, C.M. Knudson, J.J. Cullen, Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer, Clin. Cancer Res. 16 (2) (2010) 509–520.
[31] X. Wei, Y. Xu, F.F. Lu, L. Chaiswing, D. Schnell, T. Noel, C. Wang, J. Chen, D.K. St Clair, W.H. St Clair, Redox Biol. 7 (2015) 327–327.
[32] K. Polireddy, R. Dong, G. Reed, J. Yu, P. Chen, S. Williamson, P.C. Violet, Z. Pesnetko, A.K. Godwin, F. Fan, et al., High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis and a phase I/IIa study, Sci. Rep. 7 (1) (2017) 17188.
[33] E. Pena, F.J. Roa, E. Inostroza, K. Sotomayor, M. Gonzalez, P.A. Gutierrez-Castro, M. Maurin, K. Sweet, C. Labrousse, M. Gatica, et al., Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSCT2) as a central

N. El Banna, et al.
Redox Biology 26 (2019) 101290
feature in breast cancer, Free Radic. Biol. Med. 135 (2019) 283–292.

[49] J.C. Vera, C.I. Rivas, R.H. Zhang, C.M. Farber, D.W. Golde, Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid, Blood 84 (5) (1994) 1628–1634.

[50] J.M. May, Z.C. Qu, D.R. Neel, X. Li, Recycling of vitamin C from its oxidized forms by human endothelial cells, Biochim. Biophys. Acta 1640 (2–3) (2003) 153–161.

[51] C.M. Stephenson, R.D. Levin, T. Spector, C.G. Lis, Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer, Cancer Chemother. Pharmacol. 72 (1) (2013) 139–146.

[52] L.J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S.J. Padayatty, K. Rosaduk, C. Rousseau, L. Robitaille, W.H. Miller Jr., Phase I clinical trial of i.v. ascorbic acid in advanced malignancy, Ann. Oncol. 19 (11) (2008) 1969–1974.